ClinicalTrials.gg
TerminatedNCT03497715Updated Apr 13, 2018

Gamma Scintigraphy Study to Investigate Tablet Disintegration in Healthy Volunteers.

A Phase 1 interventional study of Ibuprofen lysine and Ibuprofen Sodium in Healthy Subjects, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Terminated. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-13.

Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Phase 1, Interventional, and Treatment

Why this study was terminated
On completion of part 1 it was felt that there would be no benefit in completing part 2

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Apr 2015, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The study will be an adaptive, 2 part, single dose, 5-way crossover gamma scintigraphy study in healthy subjects, to investigate the rate and site of tablet disintegration of various forms of Ibuprofen.

Read the detailed description

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and anti-pyretic properties. There are now a wide variety of formulations of ibuprofen available on market in which the active ingredient, ibuprofen, is either as the free acid, salt or salt in situ. As a result of differences between these formulations, differences in absorption and time to effectiveness are achieved. Rates of absorption are commonly assessed using pharmacokinetic (PK) studies, where the time taken for therapeutic plasma concentration levels to be reached can be determined, with associated absorption profiles being generated.

Before absorption can occur the product must disintegrate in the stomach and empty into the small intestine. Gamma scintigraphy may be used to assess the disintegration rate (of tablets/capsules/caplets) by acquiring images of the investigational medicinal product (IMP) in vivo. Through the use of radiolabelled dosage forms, it enables the visualisation of key stages preceding absorption, including tablet disintegration and the rate of gastric emptying. The assessment of these stages, which are required prior to absorption in the small intestine, may be useful in gaining an understanding of the differences between the dosage forms. The main purpose of this study is to visualise and determine the rate of disintegration and subsequent availability for absorption of different ibuprofen formulations, by gamma scintigraphy.

The study will be conducted in two parts. Part 1 will be conducted as a pilot phase where each subject will receive all 5 IMPs over 5 treatment visits (one IMP/visit).

The data generated in Part 1 will be assessed and used to determine whether to continue to Part 2 as planned, continue to Part 2 with adaptations or stop the study. Adaptations may involve altering the radiolabelling procedure and/or the gamma scintigraphy procedure and/or associated time-points and/or redefining primary/secondary endpoints and statistical analyses.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 35 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: > 18 to \< 50 years.
  2. Sex: Male.
  3. Status: Healthy volunteers.

Exclusion criteria

Exclusion Criteria:

  1. A history of significant disease of any body-system.
  2. Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.
  3. A history of allergy or intolerance (including angio-oedema, urticaria, bronchospasm and rhinitis) related to treatment with ibuprofen or other nonsteroidal anti-inflammatory drugs (NSAIDs) or the of the formulations.
  4. A history of peptic or duodenal ulcers or gastro-intestinal bleed or upper gastrointestinal bleed, or other significant gastro-intestinal disorders.
  5. A history of frequent dyspepsia, e.g., heartburn or indigestion.
  6. A history of migraine.
  7. A history of psychotic illness, attempted suicide or parasuicide.
  8. Current smokers and ex-smokers who have smoked within 6 months.
  9. A history of drug abuse (including alcohol).
  10. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc.; total caffeine intake per day above 300 mg (1 cup of coffee equates to 50 mg).
  11. Those with positive drugs of abuse screen including alcohol on any occasion throughout the study.
  12. Ingestion of a prescribed drug at any time in the 14 days before dosing with study medication (excluding hormonal and hormone replacement therapy), or consumption of enzyme inhibitors or inducers during the previous month (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc.).
  13. Ingestion of an over-the-counter preparation within 7 days before dosing with study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and other NSAIDs and paracetamol.
  14. Known human immune deficiency virus () positive status, or a positive viral serology screen.
  15. Those unable in the opinion of the Investigator to comply fully with the study requirements.
  16. Those who are unwilling to consume gelatin of animal origin.
  17. Those previously randomised into this study.
  18. Employee at study site.
  19. Partner or first degree relative of the investigator
  20. Those who have participated in a clinical trial in the previous 12 weeks.
  21. Participation in a study in which radioisotopes were administered or in which subjects were exposed to any radiation (e.g. x-rays, handling of radiolabelled materials) other than normal background radiation within the 12 months before the screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Experimental 1

    Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)

    Drug: Ibuprofen lysine · Drug: Ibuprofen Sodium · Drug: Ibuprofen · Drug: Ibuprofen (Nurofen) · Drug: Ibuprofen (Wockhardt)

  • Experimental
    Experimental 2

    Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules

    Drug: Ibuprofen lysine · Drug: Ibuprofen Sodium · Drug: Ibuprofen · Drug: Ibuprofen (Nurofen) · Drug: Ibuprofen (Wockhardt)

  • Experimental
    Experimental 3

    Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine

    Drug: Ibuprofen lysine · Drug: Ibuprofen Sodium · Drug: Ibuprofen · Drug: Ibuprofen (Nurofen) · Drug: Ibuprofen (Wockhardt)

  • Experimental
    Experimental 4

    Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium

    Drug: Ibuprofen lysine · Drug: Ibuprofen Sodium · Drug: Ibuprofen · Drug: Ibuprofen (Nurofen) · Drug: Ibuprofen (Wockhardt)

Interventions

06

What researchers measure

Primary outcomes

  1. Radioactive counts

    radioactivity counts as determined by gamma scintigraphy imaging

    Time frame: 3 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jul 2015, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Apr 13, 2018
StartActual
Apr 14, 2015
Primary completionActual
Jul 30, 2015
CompletionActual
Jul 30, 2015
Last update
Apr 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03497715
Responsible party
Sponsor
First posted
Apr 13, 2018
Start date
Apr 14, 2015
Primary completion
Jul 30, 2015
Completion
Jul 30, 2015
Last update
Apr 13, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Solufenum · Ibuprofen sodium dihydrate · Ibuprofen

Start the discussion